Indivior Pharmaceuticals, Inc. (INDV) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $487.00M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $486.00M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $29.00M; Long-term Debt, Excluding Current MaturitiesUSD $290.00M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-Term Debt, Maturity, Year OneUSD $59.00M; Long-Term Debt, Maturity, Year TwoUSD $55.00M.
Indivior Pharmaceuticals, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Borrowings USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $487.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $486.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $29.00M | $290.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $59.00M | $55.00M | $52.00M | $50.00M | $243.00M | $0.00 | (m) |
| 2025-09-30 | $18.00M | $304.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $18.00M | $308.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $18.00M | $311.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $18.00M | $315.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $53.00M | $51.00M | $57.00M | $55.00M | $52.00M | $256.00M | (m) |
| 2023-12-31 | $3.00M | $237.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $311.00M |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $324.00M |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $316.00M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |